𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mixture Modeling for the Detection of Subpopulations in a Pharmacokinetic/Pharmacodynamic analysis

✍ Scribed by Annabelle Lemenuel-diot; Christian Laveille; Nicolas Frey; Roeline Jochemsen; Alain Mallet

Publisher
Springer
Year
2006
Tongue
English
Weight
433 KB
Volume
34
Category
Article
ISSN
1573-8744

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetic–pharmacodynamic analysis
Pharmacokinetic–pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats
✍ Hisakazu Ohtani; Hitoshi Sato; Tatsuji Iga; Hajime Kotaki; Yasufumi Sawada 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 2 views

Ebastine (EBS), a novel nonsedative antiallergic agent, is similar to terfenadine in its chemical structure. However, clinical arrhythmogenicity of EBS remains controversial. In this study, we evaluated the possible arrhythmogenic potency of EBS as assessed by QT prolongation from a pharmacokinetic-

A combined pharmacokinetic–pharmacodynam
A combined pharmacokinetic–pharmacodynamic (PK–PD) model for tumor growth in the rat with UFT administration
✍ Jong Hwan Sung; Anjali Dhiman; Michael L. Shuler 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB

A combined pharmacokinetic-pharmacodynamic model was developed to simulate the response of a rat tumor to UFT, a combination of uracil with Tegafur (FT). Tegafur is oral the prodrug of 5-fluorouracil (5-FU), an anti-cancer drug for colon cancer. A physiologically based pharmacokinetic (PBPK) model w

Pharmacokinetic/pharmacodynamic modeling
Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia
✍ Ryan J. Hansen; Joseph P. Balthasar 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

Recently, our laboratory reported that intravenous immunoglobulin (IVIG) treatment increased antiplatelet antibody (7E3) clearance in a rat model of immune thrombocytopenic purpura (ITP). However, due to the multifaceted nature of IVIG therapy, the contribution of this increase in antiplatelet antib